Physician profile
Mavis Lowe
NPI 1578836987
$4,139.89
in general payments reported to CMS, 2019-2025
31 companies · $730 in 2025
The $730 reported for 2025 was more than what 79% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $680 · 2022: $1,046 · 2023: $829 · 2024: $856 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $682.07 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $644.84 | 2021-2025 | Jardiance, Ofev, Spiriva Respimat |
| Abbott Laboratories | $428.87 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $343.90 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $232.16 | 2021-2023 | Tagrisso |
| Amgen INC. | $231.53 | 2022-2025 | Tavneos, Evenity, Prolia |
| Gilead Sciences, INC. | $214.75 | 2021-2024 | Veklury |
| Lilly USA, LLC | $209.41 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $185.40 | 2022-2025 | Korlym |
| Dexcom, INC. | $157.13 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $140.91 | 2023-2025 | Zerbaxa, Recarbrio, Dificid |
| Mallinckrodt Hospital Products INC. | $84.00 | 2022-2024 | Acthar |
| Baxter Healthcare | $76.91 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Beta Bionics, INC. | $71.04 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $47.29 | 2021-2025 | Gvoke Hypopen |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $44.55 | 2022-2023 | Cimzia |
| Tandem Diabetes Care, INC. | $40.40 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Melinta Therapeutics, LLC | $40.36 | 2022 | |
| Medtronic, INC. | $39.37 | 2021 | |
| Paratek Pharmaceuticals, INC. | $31.76 | 2021-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $29.43 | 2024 | Hyqvia |
| Merz Pharmaceuticals, LLC | $24.45 | 2025 | Ampyra, Inbrija, Xeomin |
| Boston Scientific Corporation | $19.40 | 2023 | Watchman Access System |
| Sobi, INC | $18.40 | 2022 | |
| Abbvie INC. | $18.36 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.66 | 2022 | |
| Daiichi Sankyo INC. | $17.15 | 2022 | |
| Shionogi INC | $14.31 | 2021 | |
| La Jolla Pharmaceutical Company | $14.16 | 2021 | |
| Grifols USA, LLC | $14.11 | 2022 | |
| Grt US Holding, INC. | $5.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mavis Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.